January 19, 2021 7:51am

A hope, a wing and a prayer for something to fulfill which expectation

Pre-open indication: 2 SELLs and 3 BUYs

What I provide is a trusted source of share pricing intelligence that ensures that investors are kept apprised of “our” universe, the RegMed/cell and gene therapy sector and its surrounding markets

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  

Dow futures are UP +0.63% (+193 points), S&P futures are UP +0.66% (+25 points) and NASDAQ futures are UP +0.78% (+59 points)


U.S. stock futures jump “hoping” to bounce back from a rough week;

European stocks were mixed as the pan-European Stoxx 600 hovered just above the flatline;

Stocks in Asia-Pacific were mixed as the MSCI index (outside Japan) rose +1.6%.



On U.S. stocks fell on Friday while on Monday markets (were closed for Martin Luther King Day), European stocks started the new trading week slightly higher as shares in Asian-Pacific markets traded mixed.

President-elect Biden’s inaugurates tomorrow with expectations for a $1.9 trillion fiscal aid/stimulus and faster pace of vaccine distribution.

Biggest question of recent times, "when is my vaccination shot and where do i queue? 


Friday’s evening’s recap: RegMed Investors’ (RMi) closing bell: “momentum shifts into reverse” … https://www.regmedinvestors.com/articles/11724

  • The Nasdaq closed DOWN -114.14 points (-0.87%);
  • The IBB closed down -0.16% and XBI closed down -1.11%;
  • Sector volume was MODERATE with 5 of the 10-upside having higher than the 3-month average volume with the increased volume of 10 of 24-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was up +1.09 points or +4.69% at 24.34;
  • Friday’s percentage (%) of the 10-upside were +0.29% (EDIT) to +14.04% (RENE.L) while the 24-downside ranges from -0.10% (CLLS) to -6.97% (PGEN);



  • 7 positive and 3 negative closes, so far


Companies in my headlights – It’s your decision; I provide an idea and context:

Maintaining Sell:

Biostage (BSTG) closed up +$0.06 to $1.22 with 8,637 shares traded after Thursday’s -$0.02 to $1.16 with 295 shares traded after Wednesday’s -$0.00 to $1.18 with 411 shares traded, Tuesday’s $1.18 with 3,500 shares traded and last Monday’s $1.16 with 3,202 shares traded. Reiterating the WHY questions:

  • Question#1: WHY does as the share price need to be "propped or pumped" and WHICH “investor” is “stimulating” the volume?
  • Question#2: Does it have anything to do with a 52-week low of $0.80 as well as a high of $4.88, a current share price of $1.22 following the last private placement priced at $4.00?
  • Question#3: WHY the extension, “BSTG issued warrants to acquire shares of common stock with an exercise price of $3.70 per share that were exercisable until December 31, 2020. On 12/30/20, BSTG agreed to ... extend the expiration date .... to June 30, 2021 with respect to warrants exercisable for an aggregate of 122,554 shares of common stock - their only form of raising capital.
  • Question#4: Don’t U.S. public shareholders deserve accountability!
  • Question#5:  A precarious capital formation platform - they’re running-out of warrant conversions?
  • Question#6: Reiterating, WHAT is “with” the $75 million raised and all but spent on getting to an IND with … NO clinical trial initiation?
  • Question#7: WHAT is the bottom line on BSTG's future - short, near and long-term?


Fate Therapeutics (FATE) closed down -$3.81 to $113.59 after Thursday’s $117.40, Wednesday’s $113.29, Tuesday’s $112.05, and last Monday’s $112.01 with a positive +$0.09 or +0.08% aftermarket (Friday)indication;

Pluristem (PSTI) closed down -$0.10 to $8.04 after Thursday’s $8.14, Wednesday’s $8.10, Tuesday’s $8.31 and last Monday’s $8.49 and has a positive +$0.06 or +0.75% aftermarket (Friday) indication;

Mesoblast (MESO) closed down -$0.11 to $9.72 after Thursday’s $9.83, Wednesday’s $10.14, Tuesday’s $10.24 and last Monday’s $11.40 with a negative -$0.14 or -1.44% aftermarket (Friday) indication;



Global Blood Therapeutics (GBT) closed up +$0.15 to $49.52 after Thursday’s +$5.16 to $139.87, Wednesday’s -$2.93 to $134.71, Tuesday’s $137.64 and last Monday’s $141.74 with a negative -$1.51 or -3.02% aftermarket (Friday) indication;


The BOTTOM LINE: Referring to my Friday maxim, "What’s changed, there is STILL a short-term tone shift in the market.

I keep reiterating, “Sector volatility remains fluid … as I had stated, “you should take some profits even if some money is left on the table – safety is cash in your pocket of portfolio!”

Everything we hear is an opinion, not a fact. Everything we see is a perspective, not the truth." Marcus Aurelius

I deal in numbers-based facts …

“Our” sector’s earnings LPS (loss-per-share) season Is about to begin. Investors are considering whether they should ignore and wait for Q2.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.